Hikari Power Ltd Sells 100,000 Shares of Progenics Pharmaceuticals, Inc. (PGNX)

Hikari Power Ltd decreased its position in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 50.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 100,000 shares of the biotechnology company’s stock after selling 100,000 shares during the period. Hikari Power Ltd owned approximately 0.12% of Progenics Pharmaceuticals worth $627,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in shares of Progenics Pharmaceuticals by 268.7% in the first quarter. JPMorgan Chase & Co. now owns 326,562 shares of the biotechnology company’s stock worth $2,436,000 after purchasing an additional 237,992 shares during the period. UBS Group AG increased its position in shares of Progenics Pharmaceuticals by 4,046.3% in the first quarter. UBS Group AG now owns 118,044 shares of the biotechnology company’s stock worth $880,000 after purchasing an additional 115,197 shares during the period. A.R.T. Advisors LLC bought a new position in shares of Progenics Pharmaceuticals in the first quarter worth $318,000. Jane Street Group LLC increased its position in shares of Progenics Pharmaceuticals by 296.0% in the first quarter. Jane Street Group LLC now owns 48,685 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 36,391 shares during the period. Finally, Summit Trail Advisors LLC increased its position in shares of Progenics Pharmaceuticals by 13.1% in the first quarter. Summit Trail Advisors LLC now owns 73,366 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 8,495 shares during the period. Hedge funds and other institutional investors own 76.45% of the company’s stock.

Progenics Pharmaceuticals stock opened at $5.01 on Wednesday. Progenics Pharmaceuticals, Inc. has a 12-month low of $4.68 and a 12-month high of $9.42. The company has a quick ratio of 6.34, a current ratio of 6.34 and a debt-to-equity ratio of 0.68.



Progenics Pharmaceuticals (NASDAQ:PGNX) last released its earnings results on Tuesday, July 31st. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.02). Progenics Pharmaceuticals had a negative net margin of 341.41% and a negative return on equity of 94.45%. The business had revenue of $3.88 million during the quarter, compared to the consensus estimate of $3.30 million. Analysts anticipate that Progenics Pharmaceuticals, Inc. will post -0.67 earnings per share for the current year.

PGNX has been the topic of a number of recent analyst reports. BidaskClub upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 20th. Needham & Company LLC raised their price target on Progenics Pharmaceuticals from $14.00 to $16.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, July 31st. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 25th. Jefferies Financial Group restated a “buy” rating and issued a $13.00 price target on shares of Progenics Pharmaceuticals in a research report on Wednesday, August 1st. Finally, ValuEngine upgraded Progenics Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $11.69.

Progenics Pharmaceuticals Profile

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

Read More: How to Invest in an Index Fund

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply